Latest News – Page 56 – Safe Biologics

New ASBM Survey Reveals Key Safety Concern Associated with Biosimilar Naming

September 13, 2012

The Alliance for Safe Biologics released a new survey examining physician practices and perspectives with regard to biosimilar medicine identification and substitution – policy issues that remain unresolved and will have a fundamental impact on patient safety. Over 350 endocrinologists, dermatologists, oncologists, rheumatologists, nephrologists and neurologists – all specialties that prescribe biologics – responded to […]

ASBM Quoted in FDA Week Story on Naming

September 7, 2012

ASBM Executive Director Michael Reilly was quoted in the FDA Week story Stakeholders Draw Biosimilar Naming Insight From Biologic Approval. Read the article.

Dr. Dolinar Presents at Florida Association of Health Plans

September 6, 2012

On September 6, Dr. Dolinar presented an overview of biologics and biosimilars at the Florida Association of Health Plans Annual Conference. View his FAHP Presentation

ASBM to Host Roundtables on Physician Notification

July 24, 2012

The Alliance for Safe Biologic Medicines (ASBM) will host a series of roundtables beginning in September to seek input from the patient, physician and pharmacist communities on the issue of physician notification for biosimilars. The roundtables seek to build on the May 24th ASBM Advisory Board physician notification working group meeting led by Chairman Richard […]

Forbes: FDA Balances Costs, Patient Safety in the Biologics and Personalized Medicine

July 23, 2012

Good piece on biosimilars in Forbes by Jon Entine, Senior Fellow at the Center for Health & Risk Communication at George Mason University. Read FDA Balances Costs, Patient Safety in the Biologics and Personalized Medicine

President Obama Signs FDA User Fee Bill

July 10, 2012

On July 9, President Obama signed the bipartisan Food and Drug Administration Safety and Innovation Act, that reauthorizes FDA user fees and that will establish new user-fee programs for biosimilar drugs. Read more.

Alliance for Safe Biologic Medicines Responds to Supreme Court Decision

June 28, 2012

WASHINGTON – Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (ASBM) issued the following statement in response to the Supreme Court ruling on the Affordable Care Act and its impact on the Food and Drug Administration’s (FDA) creation of a biosimilar pathway. “As biosimilar medicines are introduced into the U.S. in the […]

Alliance for Safe Biologic Medicines Responds to Supreme Court Decision

June 28, 2012

WASHINGTON – Dr. Richard Dolinar, chairman of the Alliance for Safe Biologic Medicines (ASBM) issued the following statement in response to the Supreme Court ruling on the Affordable Care Act and its impact on the Food and Drug Administration’s (FDA) creation of a biosimilar pathway. “As biosimilar medicines are introduced into the U.S. in the […]

ASBM Advisory Board Members Convene on Physician Notification

June 25, 2012

ASBM Chairman Dr. Richard Dolinar convened a working group of Advisory Board members to discuss the elements of a physician notification policy for biosimilars that prioritizes patient safety.

ASBM Advisory Board Members Convene on Physician Notification

June 25, 2012

ASBM Chairman Dr. Richard Dolinar convened a working group of Advisory Board members to discuss the elements of a physician notification policy for biosimilars that prioritizes patient safety.